Abstract
The β-carbonic anhydrase from Saccharomyces cerevisiae (CA, EC 4.2.1.1), scCA, which is encoded by the Nce103 gene, is an effective catalyst for CO2 hydration to bicarbonate and protons, with a kcat of 9.4 x 105 s-1, and kcat/KM of 9.8 x 107 M-1.s-1. Its inhibition with anions and sulfonamides has been investigated, as well as its activation with amines and amino acids. Bromide, iodide and sulfamide, were the best anion inhibitors, with KIs of 8.7 - 10.8 μM. Benzenesulfonamides substituted in 2-, 4- and 3,4-positions with amino, alkyl, halogeno and hydroxyalkyl moieties had KIs in the range of 0.976 - 18.45 μM. Better inhibition (KIs in the range of 154 - 654 nM) was observed for benzenesulfonamides incorporating aminoalkyl/carboxyalkyl moieties or halogenosulfanilamides; benzene- 1,3-disulfonamides; simple heterocyclic sulfonamides and sulfanilyl-sulfonamides. The clinically used sulfonamides/sulfamate (acetazolamide, ethoxzolamide, methazolamide, dorzolamide, topiramate, celecoxib, etc.) generally showed effective scCA inhibitory activity, with KIs in the range of 82.6 - 133 nM. The best inhibitor (KI of 15.1 nM) was 4-(2-amino-pyrimidin-4-yl)-benzenesulfonamide. Ladrenaline and some piperazines incorporating aminoethyl moieties were the most effective scCA activators. These studies may lead to a better understanding of the role of this enzyme in yeasts/fungi, and since the Nce103 gene is also present in many pathogenic organisms (Candida spp., Cryptococcus neoformans, etc) they may be useful to develop antifungal drugs.
Keywords: Carbonic anhydrase, beta-class enzyme, Saccharomyces cerevisiae, yeast, sulfonamide, sulfamate, anion inhibitor, amino acid, amine, activator, β-carbonic anhydrase, Benzenesulfonamides, hydroxyalkyl moieties, halogenosulfanilamides, acetazolamide, ethoxzolamide, methazolamide, dorzolamide, topiramate, celecoxib, Cryptococcus neoformans, pyruvate carboxylase (PC), acetyl-CoA carboxylase (ACC), carbamoyl phosphate synthase (CPSase), phosphoribosylaminoimidazole (AIR), Candida albicans, Candida glabrata, scCA Catalytic Activity, orthologue genes, thiocyanate, phenylboronic acid, dichorophenamide, brinzolamide, benzolamide, sulpiride, indisulam, zonisamide, valdecoxib, sulthiame, saccharin
Current Pharmaceutical Design
Title: Saccharomyces cerevisiae β-Carbonic Anhydrase: Inhibition and Activation Studies
Volume: 16 Issue: 29
Author(s): Semra Isik, Ozen Ozensoy Guler, Feray Kockar, Meltem Aydin, Oktay Arslan and Claudiu T. Supuran
Affiliation:
Keywords: Carbonic anhydrase, beta-class enzyme, Saccharomyces cerevisiae, yeast, sulfonamide, sulfamate, anion inhibitor, amino acid, amine, activator, β-carbonic anhydrase, Benzenesulfonamides, hydroxyalkyl moieties, halogenosulfanilamides, acetazolamide, ethoxzolamide, methazolamide, dorzolamide, topiramate, celecoxib, Cryptococcus neoformans, pyruvate carboxylase (PC), acetyl-CoA carboxylase (ACC), carbamoyl phosphate synthase (CPSase), phosphoribosylaminoimidazole (AIR), Candida albicans, Candida glabrata, scCA Catalytic Activity, orthologue genes, thiocyanate, phenylboronic acid, dichorophenamide, brinzolamide, benzolamide, sulpiride, indisulam, zonisamide, valdecoxib, sulthiame, saccharin
Abstract: The β-carbonic anhydrase from Saccharomyces cerevisiae (CA, EC 4.2.1.1), scCA, which is encoded by the Nce103 gene, is an effective catalyst for CO2 hydration to bicarbonate and protons, with a kcat of 9.4 x 105 s-1, and kcat/KM of 9.8 x 107 M-1.s-1. Its inhibition with anions and sulfonamides has been investigated, as well as its activation with amines and amino acids. Bromide, iodide and sulfamide, were the best anion inhibitors, with KIs of 8.7 - 10.8 μM. Benzenesulfonamides substituted in 2-, 4- and 3,4-positions with amino, alkyl, halogeno and hydroxyalkyl moieties had KIs in the range of 0.976 - 18.45 μM. Better inhibition (KIs in the range of 154 - 654 nM) was observed for benzenesulfonamides incorporating aminoalkyl/carboxyalkyl moieties or halogenosulfanilamides; benzene- 1,3-disulfonamides; simple heterocyclic sulfonamides and sulfanilyl-sulfonamides. The clinically used sulfonamides/sulfamate (acetazolamide, ethoxzolamide, methazolamide, dorzolamide, topiramate, celecoxib, etc.) generally showed effective scCA inhibitory activity, with KIs in the range of 82.6 - 133 nM. The best inhibitor (KI of 15.1 nM) was 4-(2-amino-pyrimidin-4-yl)-benzenesulfonamide. Ladrenaline and some piperazines incorporating aminoethyl moieties were the most effective scCA activators. These studies may lead to a better understanding of the role of this enzyme in yeasts/fungi, and since the Nce103 gene is also present in many pathogenic organisms (Candida spp., Cryptococcus neoformans, etc) they may be useful to develop antifungal drugs.
Export Options
About this article
Cite this article as:
Isik Semra, Ozensoy Guler Ozen, Kockar Feray, Aydin Meltem, Arslan Oktay and T. Supuran Claudiu, Saccharomyces cerevisiae β-Carbonic Anhydrase: Inhibition and Activation Studies, Current Pharmaceutical Design 2010; 16 (29) . https://dx.doi.org/10.2174/138161210793429878
DOI https://dx.doi.org/10.2174/138161210793429878 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Use of Machine Learning in MicroRNA Diagnostics: Current
Perspectives
MicroRNA The Promise of Dolutegravir: A Novel Second Generation Integrase Strand Transfer Inhibitor
Current Clinical Pharmacology Are Topological Properties of Drug Targets Based on Protein-Protein Interaction Network Ready to Predict Potential Drug Targets?
Combinatorial Chemistry & High Throughput Screening Granulomatous Lung Disease. Disease for Pulmomologists: Diagnosis and Treatment
Current Respiratory Medicine Reviews Design, Synthesis and In Vitro Antimalarial Evaluation of New Quinolinylhydrazone Derivatives
Letters in Drug Design & Discovery Inhibitors of Mycothiol-S-Conjugate Amidase and Related Genes
Current Medicinal Chemistry - Anti-Infective Agents Synthesis and In vitro Antibacterial, Antitubercular Studies of Novel Fluoroquinolones Analogs Containing 4-substituted Sec Amine
Current Bioactive Compounds Nanomedicine: Magnetic Nanoparticles and their Biomedical Applications
Current Medicinal Chemistry Potential of Nanocarriers in Genetic Immunization
Recent Patents on Drug Delivery & Formulation The Role and Potential Therapeutical Applications of Antimicrobial Proteins in Infectious and Inflammatory Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Taming the Devil: Antimicrobial Peptides for Safer TB Therapeutics
Current Protein & Peptide Science Individual Case Safety Reports Analysis for Patients with Diabetes Mellitus on Insulin in Africa and the Middle East
Current Drug Safety Ligustrazine Derivatives. Part 8: Design, Synthesis, and Preliminary Biological Evaluation of Novel Ligustrazinyl Amides as Cardiovascular Agents
Medicinal Chemistry Tuberculosis: Current Treatment, Diagnostics, and Newer Antitubercular Agents in Clinical Trials
Infectious Disorders - Drug Targets Synthesis and Antitubercular Activity of a Series of Thiazole Derivatives
Anti-Infective Agents Advances in Therapy for Psoriasis: An Overview of Infliximab, Etanercept, Efalizumab, Alefacept, Adalimumab, Tazarotene, and Pimecrolimus
Current Pharmaceutical Design Carbonic Anhydrase Inhibition/Activation: Trip of a Scientist Around the World in the Search of Novel Chemotypes and Drug Targets
Current Pharmaceutical Design New Insights into Lipidic Secondary Metabolites in Mycobacteria
Current Chemical Biology Shikimate Kinase Inhibitors: An Update on Promising Strategy against <i>Mycobacterium tuberculosis</i>
Current Drug Targets Bacterial Resistance to Antimicrobial Host Defenses - An Emerging Target for Novel Antiinfective Strategies?
Current Drug Targets